Intranet

Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria This grant program supports research on CDKL5 Deficiency Disorder (CDD). Applications should focus on advancing the discovery or development of treatments and/or potential cures.
Característiques principals Priority will be given to projects that cover the following areas: Novel therapeutic approaches for CDD, including gene and RNA-based therapies, biologics, cell-based therapeutics, small molecules, network modulation, and novel delivery systems. Link between CDKL5 molecular function and disease pathophysiology, using cellular and animal models to assess phenotypic rescue or modulation through pharmacological or genetic/gene therapy interventions. Systems biology and computational modeling approaches to understand CDKL5 function, downstream effectors, signaling pathways, interaction networks, and genetic modifiers. Discovery and validation of CDKL5 biomarkers and clinical outcomes, including molecular, imaging, electrophysiological, and functional biomarkers with translational relevance.
Lloc de presentació HMRIB and PSMAR staff who need more information should contact: Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00. Carol Barnwell: [email protected] Ext.: 1670 Marta López: [email protected] Ext.: 1576 Júlia Vidal: [email protected] Ext.: 1736
Convocatòria (URL) https://www.orphandiseasecenter.med.upenn.edu/grants/cdkl5-programs-of-excellence-pilot-grant-program-2026
Requisits All individuals holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation.
Dotació $150,000
Durada One year
Documentació Applicants must submit their LOI through: https://orphandiseasecenter.submittable.com/submit/346721/2026-cdkl5-program-of-excellence-pilot-grant-program-loi

Arxius

Arxiu
2026+CDKL5+Pilot+Grant+RFA+FINAL1.pdf